Pharmacist Resources
REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).
REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
REVLIMID REMS® information for certified pharmacies
REVLIMID is only dispensed from REVLIMID REMS® program certified pharmacies.
As a REVLIMID REMS® certified pharmacy, you must follow the requirements of the REVLIMID REMS® program. You may download a guide to the program, a checklist for counseling patients, and the full prescribing information below.
The Celgene REMS Pharmacy Portal
In addition to calling the Celgene Customer Care Center to obtain a confirmation number for a prescription, eligible pharmacies can obtain confirmation numbers using the Celgene REMS Pharmacy Portal at CelgeneREMSPharmacyPortal.com. Contact your Celgene Account Manager to see if your pharmacy is eligible.
Please report adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID to Celgene using any of the following methods:
REPORTING TO CELGENE |
|
Online: |
|
Email: |
|
Telephone: 1-908-673-9667 |
|
Toll-free: 1-800-640-7854 (Global Drug Safety & Risk Management) or |
|
Fax: 1-908-673-9115 |
|
Mail to: Global Drug Safety & Risk Management |
|
Other: Per individual agreement between the reporting organization and Celgene Global Drug Safety & Risk Management |
REPORTING TO THE FDA |
|
Adverse drug experiences that are suspected to be associated with the use of REVLIMID and
|
|
Online: |
|
Telephone: 1-800-FDA-1088 |
|
Fax: 1-800-FDA-0178 |
|
Mail to: MedWatch |
For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
© 2013-2017. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.
